D.A. Davidson & CO. Has $1.96 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

D.A. Davidson & CO. grew its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 88,919 shares of the company’s stock after purchasing an additional 2,408 shares during the period. D.A. Davidson & CO.’s holdings in Teva Pharmaceutical Industries were worth $1,960,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Smithfield Trust Co lifted its holdings in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after purchasing an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at about $50,000. Ameliora Wealth Management Ltd. bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $66,000. Venturi Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at about $60,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 273.5% in the third quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock valued at $82,000 after purchasing an additional 3,323 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $16.75 on Friday. The business’s 50 day moving average price is $19.92 and its two-hundred day moving average price is $18.49. The company has a market cap of $18.97 billion, a PE ratio of -11.55, a price-to-earnings-growth ratio of 1.44 and a beta of 0.71. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Finally, UBS Group dropped their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.57.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.